JPWO2020219766A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020219766A5 JPWO2020219766A5 JP2021563234A JP2021563234A JPWO2020219766A5 JP WO2020219766 A5 JPWO2020219766 A5 JP WO2020219766A5 JP 2021563234 A JP2021563234 A JP 2021563234A JP 2021563234 A JP2021563234 A JP 2021563234A JP WO2020219766 A5 JPWO2020219766 A5 JP WO2020219766A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- raav
- sequence
- sequences
- mirna target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837947P | 2019-04-24 | 2019-04-24 | |
| US62/837,947 | 2019-04-24 | ||
| PCT/US2020/029642 WO2020219766A1 (fr) | 2019-04-24 | 2020-04-23 | Compositions utiles dans le traitement du syndrome de rett |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022530095A JP2022530095A (ja) | 2022-06-27 |
| JPWO2020219766A5 true JPWO2020219766A5 (fr) | 2023-04-28 |
Family
ID=72941315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563234A Pending JP2022530095A (ja) | 2019-04-24 | 2020-04-23 | レット症候群の治療に有用な組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220202960A1 (fr) |
| EP (1) | EP3973060A4 (fr) |
| JP (1) | JP2022530095A (fr) |
| KR (1) | KR20220003553A (fr) |
| CN (1) | CN114026236A (fr) |
| AU (1) | AU2020261051A1 (fr) |
| CA (1) | CA3133889A1 (fr) |
| SG (1) | SG11202111279QA (fr) |
| WO (1) | WO2020219766A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023526310A (ja) * | 2020-05-12 | 2023-06-21 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 導入遺伝子発現のｄｒｇ特異的低減のための組成物 |
| WO2022094078A1 (fr) * | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions utiles dans le traitement du syndrome de rett |
| WO2023205657A2 (fr) * | 2022-04-18 | 2023-10-26 | City Of Hope | Compositions pour restaurer la fonction du gène mecp2 et leurs méthodes d'utilisation |
| WO2024081551A1 (fr) * | 2022-10-10 | 2024-04-18 | Passage Bio, Inc. | Procédé de purification de particules d'aav entièrement recombinés |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006069584A2 (fr) * | 2004-12-29 | 2006-07-06 | Exiqon A/S | Nouvelles compositions d'oligonucleotides et sequences de sondes utiles pour la detection et l'analyse de microarn et de leurs marn cibles |
| KR20130114758A (ko) * | 2005-05-27 | 2013-10-17 | 오스페달레 산 라파엘 에스.알.엘. | Ｍｉ-ｒｎａ를 포함하는 유전자 벡터 |
| CA2647125C (fr) * | 2006-04-07 | 2015-02-03 | Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts | Sequence mecp2 synthetique utilisee dans une therapie de substitution de proteines |
| US9415121B2 (en) * | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
| DE18200782T1 (de) * | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| EP3452101A2 (fr) * | 2016-05-04 | 2019-03-13 | CureVac AG | Arn codant pour une protéine thérapeutique |
| HRP20240257T1 (hr) * | 2017-02-28 | 2024-05-24 | The Trustees Of The University Of Pennsylvania | Adeno-povezani virusni (aav) clade f vektor i njegova uporaba |
| WO2018172794A1 (fr) * | 2017-03-24 | 2018-09-27 | The University Court Of The University Of Edinburgh | Thérapie à base de mecp2 |
| SG11201911737PA (en) * | 2017-06-06 | 2020-01-30 | Univ Massachusetts | Self-regulating aav vectors for safe expression of mecp2 in rett syndrome |
-
2020
- 2020-04-23 CN CN202080046692.7A patent/CN114026236A/zh active Pending
- 2020-04-23 KR KR1020217037510A patent/KR20220003553A/ko unknown
- 2020-04-23 JP JP2021563234A patent/JP2022530095A/ja active Pending
- 2020-04-23 US US17/605,827 patent/US20220202960A1/en active Pending
- 2020-04-23 AU AU2020261051A patent/AU2020261051A1/en active Pending
- 2020-04-23 EP EP20795847.1A patent/EP3973060A4/fr active Pending
- 2020-04-23 WO PCT/US2020/029642 patent/WO2020219766A1/fr unknown
- 2020-04-23 CA CA3133889A patent/CA3133889A1/fr active Pending
- 2020-04-23 SG SG11202111279QA patent/SG11202111279QA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Powell et al. | Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy | |
| Daya et al. | Gene therapy using adeno-associated virus vectors | |
| US11344608B2 (en) | Factor IX gene therapy | |
| JP2020537544A5 (fr) | ||
| JPWO2020132455A5 (fr) | ||
| Lu | Recombinant adeno-associated virus as delivery vector for gene therapy—a review | |
| US11938197B2 (en) | Polynucleotides and vectors for the expression of transgenes | |
| JP2018108113A5 (fr) | ||
| JP2018522529A5 (fr) | ||
| JP2020522269A5 (fr) | ||
| JP2020537542A5 (fr) | ||
| JP6824169B2 (ja) | 改変ｇ６ｐｃをコードするアデノ随伴ウイルスベクターおよびその使用 | |
| CA3125770A1 (fr) | Procedes et systemes de fabrication de particules aav | |
| Snyder et al. | Viral vector-mediated gene transfer for CNS disease | |
| JPWO2020223231A5 (fr) | ||
| WO2023283962A1 (fr) | Capside aav modifiée pour thérapie génique et méthodes associées | |
| JPWO2020223232A5 (fr) | ||
| Gan et al. | Gene delivery with viral vectors for cerebrovascular diseases | |
| JP2023544947A (ja) | 昆虫細胞内で重複オープンリーディングフレームを含む遺伝子を発現するための発現カセット及びその使用 | |
| JPWO2020219766A5 (fr) | ||
| US20220213494A1 (en) | Dual leucine zipper kinase inhibitors for gene therapy | |
| US20220010332A1 (en) | Intron fragments | |
| JPWO2020227166A5 (fr) | ||
| CA3218360A1 (fr) | Systeme de production de vaar a haut niveau | |
| JPWO2021231579A5 (fr) |